Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.40 |
| ▸ | PDE9A | O76083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5521419 | 0.84 | HDAC1 (0.49) | HDAC1HDAC2HDAC3 | |
| SCHEMBL5528685 | 0.84 | HDAC1 (0.51) | HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL4979090 | 0.83 | HDAC1 (0.52) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL4982200 | 0.82 | HDAC1 (0.43) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL5533500 | 0.78 | HDAC1 (0.52) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL3538371 | 0.77 | HDAC1 (0.53) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL3538368 | 0.77 | HDAC1 (0.53) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL4979149 | 0.72 | HDAC1 (0.54) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| Hydrochloric Acid SCHEMBL15575604 | 0.71 | ITK (0.62) | HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL4973077 | 0.69 | HDAC1 (0.55) | HDAC1HDAC8HDAC6HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173527-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-07-26 | — | — | US | claimed |
| WO-2007084390-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173527-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-07-26 | — | — | US | disclosed |
| US-20070173527-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-07-26 | — | — | US | disclosed |
| US-20070173527-A1 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173527-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC2 | HDAC1 1/4885HDAC8 5/4885HDAC6 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.